ACCESSIBILITY OF ORPHAN DRUGS IN FRANCE, UNITED KINGDOM AND GERMANY: DIFFERENT APPROACHES WITH REGARD TO HTA AND PRICES

被引：0
|
作者：
Grandfils, N. [1 ]
Hounkanlin, H. [1 ]
Troubat, A. [1 ]
机构：
[1] IMS Hlth, Paris, France
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.773
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A457 / A457
页数：1
相关论文
共 50 条
  • [31] HTA criteria adopted in different models of public healthcare systems for orphan drugs: A scoping review
    Felippini, Arturo
    Biglia, Luiza Vasconcelos
    Lima, Tacio de Mendonca
    Aguiar, Patricia Melo
    [J]. HEALTH POLICY, 2024, 144
  • [32] Approval of new drugs in the United States - Comparison with the United Kingdom, Germany, and Japan
    Kessler, DA
    Hass, AE
    Feiden, KL
    Lumpkin, M
    Temple, R
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (22): : 1826 - 1831
  • [33] Divergent Interests and Different Success Rates: France, Germany, Italy, and the United Kingdom in EU Legislative Negotiations
    Torsten J Selck
    Michael Kaeding
    [J]. French Politics, 2004, 2 (1) : 81 - 95
  • [34] Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany
    Shibata, Shoyo
    Uemura, Ryotaro
    Suzuki, Takeshi
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (02) : 221 - 227
  • [35] Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany
    Shoyo Shibata
    Ryotaro Uemura
    Takeshi Suzuki
    [J]. Therapeutic Innovation & Regulatory Science, 2016, 50 : 221 - 227
  • [36] PRICES OF DRUGS FOR CHRONIC USE WITH ORPHAN DESIGNATION IN THE UNITED STATES (1983-2014)
    Alhawwashi, S.
    Seoane-Vazquez, E.
    Eguale, T.
    Rodriguez-Monguio, R.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A4 - A4
  • [37] Cardiovascular and Renal Morbidity in Gout Patients in Germany, United Kingdom, United States, and France
    Nyberg, Fredrik
    Nuevo, Javier
    Horne, Laura
    Morlock, Robert
    Storgard, Chris
    Aiyer, Lalitha
    Hines, Dionne M.
    Ansalobehere, Xavier
    Chevalier, Pierre
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 376 - 376
  • [38] LEARNING THE LESSONS OF ONCOLOGY HTA REVIEWS IN AUSTRALIA & THE UNITED KINGDOM - A CASE STUDY OF FIVE DRUGS
    Lewis, S.
    Dummett, H.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A175 - A175
  • [39] Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom
    Hechmati, G.
    Arellano, J.
    Mohamed, A.
    Hauber, B.
    Qian, Y.
    Gatta, F.
    Haynes, I.
    Bahl, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S337 - S337
  • [40] Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom
    Hechmati, Guy
    Hauber, A. Brett
    Arellano, Jorge
    Mohamed, Ateesha F.
    Qian, Yi
    Gatta, Francesca
    Haynes, Ian
    Bahl, Amit
    von Moos, Roger
    Body, Jean-Jacques
    [J]. SUPPORTIVE CARE IN CANCER, 2015, 23 (01) : 21 - 28
12345